stockrow
Friday 6 November 2026
Export SNY’s income statement to Excel — free account
Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
46.81
0.66
−1.39%
Follow SNY
Alert me
Sanofi (SNY) Revenue
Sanofi's revenue for fiscal 2025 was $52.9B, up 10.3% from $47.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $59.1B. Over the past ten years it has ranged from $38.4B (fiscal 2016) to $52.9B (fiscal 2025) — the current reading is the highest in ten years. Sanofi ranks 7th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $52.9B | 10.29% |
| FY2024 | $47.9B | (4.66%) |
| FY2023 | $50.3B | 5.11% |
| FY2022 | $47.8B | 3.18% |
| FY2021 | $46.3B | 8.58% |
| FY2020 | $42.7B | 1.28% |
| FY2019 | $42.1B | 0.03% |
| FY2018 | $42.1B | 2.96% |
| FY2017 | $40.9B | 6.54% |
| FY2016 | $38.4B | (0.78%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $17.5B | 22.60% |
| Jun 2026 | $14.3B | 8.67% |
| Mar 2026 | $13.2B | (6.67%) |
| Dec 2025 | $14.1B | (8.41%) |
| 39 more quarters | Free account |
Against its own ten years
Low $38.4B
High $52.9B
Ten-year median
$42.7B
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| SNY Sanofi | $59.1B |
| NVS Novartis AG compare | $57.4B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| GSK GSK PLC Sponsored ADR compare | $44.9B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SNY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement